| Market Capitalization (Millions $) |
30 |
| Shares
Outstanding (Millions) |
7 |
| Employees |
55 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-84 |
| Cash Flow (TTM) (Millions $) |
6 |
| Capital Exp. (TTM) (Millions $) |
0 |
Kezar Life Sciences Inc
Kezar Life Sciences Inc. is a biotechnology company that was founded in 2015 and is headquartered in South San Francisco, California. The company is focused on developing new therapies for autoimmune diseases and cancer by targeting the immune system. Kezar is dedicated to discovering and developing novel small molecule therapeutics that modulate the immune system and address unmet medical needs.
Kezares lead program is focused on the development of KZR-616, a selective immunoproteasome inhibitor, which is being developed for the treatment of autoimmune diseases such as lupus nephritis, dermatomyositis, and polymyositis. It is also being developed for the treatment of severe COVID-19 patients with acute respiratory distress syndrome (ARDS).
The company's approach is based on the concept of selective immunoproteasome inhibition. The immunoproteasome is a complex of protein-degrading enzymes that are highly expressed in immune cells and play a critical role in immune system function. By selectively inhibiting the immunoproteasome, Kezar believes it can develop therapeutics that help restore balance to the immune system in autoimmune disease and enhance the immune system in cancer.
In addition to KZR-616, Kezar has a pipeline of additional compounds that target different aspects of the immune system. These include small molecule inhibitors of other proteolytic complexes, such as the caspase-1 inflammasome for the treatment of inflammatory diseases.
Kezar has an experienced management team, with a track record of drug development success. The company has raised over $103 million in venture capital funding, and in 2018, it went public on the NASDAQ stock exchange under the ticker symbol KZR.
Kezares approach to immunotherapy has the potential to transform the way autoimmune diseases and cancer are treated. The company is dedicated to bringing its innovative therapeutics to patients with unmet medical needs around the world.
Company Address: 4000 Shoreline Court South San Francisco 94080 CA
Company Phone Number: 822-5600 Stock Exchange / Ticker: NASDAQ KZR
|
3.78%